Gene expression patterns in the histopathological classification of epithelial ovarian cancer

Zhu,Honglan; Yu,Jing J.

doi:10.3892/etm_00000030

Gene expression patterns in the histopathological classification of epithelial ovarian cancer

Authors:
- Honglan Zhu
- Jing J. Yu
View Affiliations

Affiliations: Department of Biochemistry, School of Medicine, Department of Basic Pharmaceutical Sciences, School of Pharmacy and Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000030
Pages: 187-192

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to screen cancer-related genes and to identify histopathological gene expression patterns as potential biomarkers in human epithelial ovarian cancer (EOC). Fifty genes were screened by reverse-transcription polymerase chain reaction assay with cDNA from 83 EOC tissues and 48 normal ovarian specimens of ovarian cancer patients and evaluated by gel electrophoresis analysis. Twenty expressed genes were assessed by real-time relative-quantity (RQ)-PCR in 30 EOC specimens for gene signature study. Four genes, TAL2, EGF, ILF3 and UBE2I, were investigated for gene expression patterns in histopathological classification of EOC. RQ-value (Ct, ΔCt, ΔΔCt, RQ and gene expression plots) was generated by ABI 7500 Fast System SDS Software (version 1.4). SPSS 15.0 software was used for statistical analysis. Using real-time RQ-PCR, we found that TAL2, EGF, ILF3 and UBE2I demonstrated distinct expression patterns in histological types of epithelial ovarian cancer. The expression of ILF3 and UBE2I in tumors was significantly higher than in normal tissue, with extremely high expression in serous carcinomas compared to mucinous, endometrium and clear cell carcinomas. In addition, ILF3 and UBE2I were overexpressed in advanced stage and advanced grade ovarian cancer, compared to early stage or well-differentiated ovarian cancer. This is the first report of TAL2 and ILF3 expression in the normal human ovary and epithelial ovarian cancer. Our results indicate that overexpression of ILF3 and UBE2I in advanced stage and advanced grade suggest that these two genes may play an important role in tumorigenesis/tumor progression and pathological differentiation of the disease. Notably, ILF3 plays a role in DNA binding activity and transcriptional and post-transcriptional regulation; UBE2I is required in ubiquitination and sumoylation and is involved in DNA repair and apoptosis of cells. Further investigations to reveal the molecular mechanisms related to the activation of ILF3 and UBE2I in the development of EOC are warranted.

View Figures

View References

1.	Shih IM and Kurman RJ: Ovarian tumorigenesis. Am J Pathol. 164:1511–1518. 2004. View Article : Google Scholar
2.	Baranova A, Gowder S, Naouar S, et al: Expression profile of ovarian tumors distinct signature of Sertoli-Leydig cell tumor. Int J Gynecol Cancer. 16:1963–1972. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Yu JJ: Unlocking the molecular mechanisms of DNA repair and platinum drug resistance in cancer chemotherapy. Curr Drug Ther. 4:19–28. 2009. View Article : Google Scholar
4.	Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol. 18:19–32. 2005. View Article : Google Scholar
5.	Cecco LD, Marchionni L, Gariboldi M, et al: Gene expression profiling of advanced ovarian cancer characterization of a molecular signature involving fibroblast growth factor 2. Oncogene. 23:8171–8183. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Tothill RW, Tinker AV, Joshy G, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Reed E, Yu JJ, Davies A, Gannon J and Armentrout SL: Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res. 9:5299–5305. 2003.PubMed/NCBI
8.	Schwartz DR, Kardia SLR, Shedden KA, et al: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 62:4722–4729. 2002.
9.	Fehrmann RS, Li XY, van Der Zee AG, de Jong S, Te Meerman GJ, de Vries EG and Crijns AP: Profiling studies in ovarian cancer: a review. The Oncologist. 12:960–966. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Yu JJ, Dabholkar M, Bennett WP, Welsh JA, Mu CJ, Bostick-Bruton F and Reed E: Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA. Int J Oncol. 8:313–317. 1996.PubMed/NCBI
11.	Pinheiro P, Gering M and Patient R: The basic helix-loop-helix transcription factor, TAL2, marks the lateral floor plate of the spinal cord in zebrafish. Gene Expr Patterns. 4:85–92. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Bucher K, Sofroniew MV, Pannell R, et al: The T cell oncogene Tal2 is necessary for normal development of the mouse brain. Dev Biol. 227:533–544. 2000. View Article : Google Scholar : PubMed/NCBI
13.	Ferrando AA, Neuberg DS, Staunton J, et al: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1:75–87. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Wong AST and Leung PCK: Role of endocrine and growth factors on the ovarian surface epithelium. J Obstet Gynaecol Res. 33:3–16. 2007. View Article : Google Scholar
15.	Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S and Auersperg N: Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol. 290:1532–1542. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Stromberg K, Johnson GR, O'Connor DM, Sorensen CM, Gullick WJ and Kannan B: Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis. Int J Gynecol Pathol. 13:342–347. 1994. View Article : Google Scholar : PubMed/NCBI
17.	Niikura H, Sasano H, Sato Sh and Yajima A: Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol. 16:60–68. 1997. View Article : Google Scholar : PubMed/NCBI
18.	Cazanove O, Batut J, Scarlett G, et al: Methylation of XILF3 by Xprmt1b alters its DNA, but not RNA, binding activity. Biochemistry. 47:8350–8357. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Saunders LR and Barber GN: The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J. 17:961–983. 2003. View Article : Google Scholar : PubMed/NCBI
20.	Vumbaca F, Phoenix KN, Rodriguez-Pinto D, Han DK and Claffey KP: Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation and breast cancer angiogenesis. Mol Cell Biol. 28:772–783. 2008. View Article : Google Scholar
21.	Schumacher JJ, Dings RPM, Cosin J, Subramanian IV, Auersperg N and Ramakrishnan S: Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res. 67:3683–3690. 2007. View Article : Google Scholar : PubMed/NCBI
22.	Bermudez Y, Yang H, Saunders BO, Cheng JQ, Nicosia SV and Kruk PA: VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent. Gynecol Oncol. 106:526–537. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Moschos SJ and Mo YY: Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis. J Mol Hist. 37:309–319. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Mo YY, Yu Y, Theodosiou E, Ee PL and Beck WT: A role for Ubc9 in tumorigenesis. Oncogene. 24:2677–2683. 2005. View Article : Google Scholar : PubMed/NCBI
25.	Dűnnebier T, Bermejo JL, Haas S, et al: Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade. Int J Cancer. 125:596–602. 2009.